Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376481 | 0.91 | ALDH1A1 (0.46) | KDM4EPOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL1020021 | 0.75 | POLB (0.72) | KDM4EPOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2807505 | 0.71 | POLB (0.56) | KDM4EPOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL3721054 | 0.71 | KDM4E (0.49) | KDM4EPOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL13012640 | 0.71 | PIK3CA (0.49) | PIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL13872584 | 0.71 | PIK3CA (0.58) | PIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL4234859 | 0.71 | KDM4E (0.46) | KDM4EPOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL12247675 | 0.70 | ALDH1A1 (0.56) | KDM4EPOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2378251 | 0.70 | HTR2C (0.44) | KDM4EPOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2812176 | 0.70 | GAA (0.41) | KDM4EPOLBSMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024023766-A1 | P13K INHIBITOR COMBINATION THERAPY | BERLIN-CHEMIE AG (DE) | 2024-02-01 | — | — | WO | claimed |
| WO-2024023766-A1 | P13K INHIBITOR COMBINATION THERAPY | BERLIN-CHEMIE AG (DE) | 2024-02-01 | — | — | WO | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20130123255-A1 | COMBINATION OF A PI3K INHIBITOR AND A MEK INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-05-16 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | KDM4E 2852/4885POLB 453/4885SMN1; SMN2 3098/4885 |
| US-20130123255-A1 | COMBINATION OF A PI3K INHIBITOR AND A MEK INHIBITOR | BRAF, JAK2, NRAS | KDM4E 1306/4885POLB 1320/4885SMN1; SMN2 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.